Annovis Bio, INC 8-K filings

Annovis Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all five proposals, including director elections and equity plan amendments, were approved.

Annovis Bio reports Q1 2026 financial results while highlighting significant enrollment progress in its Phase 3 Alzheimer's and Parkinson's clinical trials.

Annovis Bio, Inc. announced the departure of Chief Financial Officer Mark Guerin, with CEO Maria Maccecchini assuming the role on an interim basis.

Annovis Bio announced its fiscal year 2025 financial results and provided updates on its pivotal Phase 3 Alzheimer's disease study and open-label Parkinson's disease study.

Annovis Bio receives positive DSMB recommendation for buntanetap's safety, allowing its pivotal Phase 3 Alzheimer's disease trial to continue without modification.

Annovis Bio provided an update on its buntanetap clinical programs for Alzheimer's and Parkinson's diseases, detailing progress in pivotal Phase 3 AD enrollment and the initiation of a Parkinson's Open Label Extension study.

Annovis Bio reported third quarter 2025 financial results, highlighting significant progress in its pivotal Phase 3 Alzheimer's study, strengthened intellectual property, and a bolstered cash position.

Annovis Bio, Inc. announced a registered direct offering of common stock and warrants, raising approximately $3.425 million to fund its Alzheimer's Phase 3 study.

Annovis Bio, Inc. announced a registered direct offering of common stock and pre-funded warrants, raising approximately $6 million to fund its Phase 3 Alzheimer's study and for general corporate purposes.

Annovis Bio, a late-stage clinical drug platform company, announced the appointment of Mark Guerin as its new Chief Financial Officer, effective September 25, 2025.

Annovis Bio, Inc. announced the resignation of its Vice President of Finance, Andrew Walsh, with CEO Maria Maccecchini appointed as Acting Chief Financial Officer.

Annovis Bio announced its second quarter 2025 financial results and provided updates on its pivotal Phase 3 Alzheimer's disease trial, which is rapidly advancing enrollment.

Annovis Bio, Inc. announced that its stockholders approved all proposals, including the re-election of five directors and the ratification of Ernst & Young LLP as independent auditors, at its 2025 Annual Meeting held virtually on June 17, 2025.

Annovis Bio, Inc. announced that the New York Stock Exchange has accepted its plan to regain compliance with minimum market capitalization and stockholders' equity listing standards, granting an 18-month cure period.

Annovis Bio announces Q1 2025 financial results, highlighting the initiation of a pivotal Phase 3 clinical trial for Alzheimer's disease and providing a corporate update.

Annovis Bio, Inc. received a notice from the NYSE regarding non-compliance with continued listing standards due to its market capitalization and stockholders' equity falling below the required thresholds.

Annovis Bio reports promising clinical trial results for buntanetap in Alzheimer's and Parkinson's disease, along with its fourth quarter and full-year 2024 financial results.

Annovis Bio has commenced its Phase 3 clinical trial for Buntanetap, a drug targeting early Alzheimer's disease, with the first patients now enrolled.

Annovis Bio has priced a $21 million public offering of common stock and warrants to advance its Alzheimer's disease drug, Buntanetap.

Annovis Bio is progressing its drug, Buntanetap, towards Phase 3 trials for both Alzheimer's and Parkinson's diseases, supported by recent financing and positive clinical data.

Annovis Bio has entered into an agreement to sell up to $50 million of its common stock through an at-the-market offering program.

Annovis Bio, Inc. has appointed William Fricker as interim Chief Financial Officer, effective December 4, 2024.

Annovis Bio has received FDA clearance to begin Phase 3 trials for its Alzheimer's drug, buntanetap, and has secured sufficient funding to initiate the studies.

Annovis Bio has been granted FDA clearance to proceed with pivotal Phase 3 studies for its Alzheimer's drug, buntanetap, following a successful End-of-Phase 2 meeting.

Annovis Bio has filed three new patents for combination therapies involving its lead compound, buntanetap, with Trulicity and Viagra, showing potential for enhanced cognitive function in neurodegenerative diseases.

Annovis Bio reported encouraging clinical trial results for its drug buntanetap in Alzheimer's and Parkinson's disease, along with its second quarter 2024 financial results.

Annovis Bio announced preclinical data demonstrating that its lead compound, buntanetap, when combined with a GLP-1 agonist, showed a synergistic effect in improving cognitive function in a mouse model of Alzheimer's disease.

Annovis Bio has secured FDA approval to transition to a new crystal form of its drug candidate, buntanetap, for future clinical trials.

Annovis Bio, Inc. has received $7 million in gross proceeds from the exercise of 0.8 million warrants issued in November 2023.

Annovis Bio's Phase III study of buntanetap in Parkinson's patients demonstrates statistically significant improvements in motor and cognitive functions.